An EORTC Study Updating the QLQ-BR23 to BR45
Launched by UNIVERSITY OF LEEDS · Feb 13, 2020
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Adult females aged 18 years or over
- • Histologically confirmed diagnosis of breast cancer (any type) with no previous primary or recurrent tumour
- • Receiving or have previously received curative or palliative treatment.
- • Able to understand/speak English and complete the questionaires
- • Have the capacity/mental fitness to give written informed consent and complete the questionnaires.
- Exclusion Criteria:
- • Male gender or transgender
- • Inability to understand/speak English and complete the questionnaire
- • Patients with any psychiatric condition or cognitive impairment, as determined by the treating physician, that would hamper participation.
About University Of Leeds
The University of Leeds is a prestigious research institution located in the United Kingdom, renowned for its commitment to advancing knowledge through innovative research and education. As a clinical trial sponsor, the University of Leeds leverages its diverse expertise and collaborative environment to facilitate high-quality clinical studies that aim to improve health outcomes and contribute to the scientific community. The university fosters interdisciplinary partnerships, ensuring rigorous methodologies and ethical standards in its research initiatives. By integrating cutting-edge technologies and a patient-centered approach, the University of Leeds plays a vital role in translating research findings into practical applications for healthcare improvement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leeds, West Yorkshire, United Kingdom
Patients applied
Trial Officials
Galina Velikova
Principal Investigator
University of Leeds
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials